NeoPred, a dual-phase CT AI tool, accurately predicts major pathological response in NSCLC patients preoperatively.
Key Details
- 1NeoPred combines pre-treatment and pre-surgery CT scans with clinical data to predict major pathological response (MPR) in NSCLC undergoing neoadjuvant chemo-immunotherapy.
- 2Study included 509 patients across four oncology centers (459 retrospective, 50 prospective, 59 external validation).
- 3NeoPred reached AUCs of 0.772 (imaging only) and 0.787 (imaging plus clinical data) on external validation, outperforming thoracic surgeons (AUC 0.760 vs 0.720) in prospective testing.
- 4AI support improved surgeons' AUC to 0.829 and diagnostic accuracy to 82%.
- 5NeoPred identified 'pseudo-stable' responders missed by standard RECIST criteria, with AUCs of 0.742 (external) and 0.833 (prospective).
Why It Matters
Accurately predicting response before surgery could enable earlier, evidence-based clinical decisions for NSCLC, reducing overtreatment and personalizing care. This work demonstrates the expanding role and performance advantage of AI-assisted imaging over traditional assessment in complex oncologic management.
Source
EurekAlert
Related News
•EurekAlert
Study Warns: AI Alone Is Not Enough in Critical Healthcare Decisions
Evaluating both AI algorithms and human users is key for safe adoption in high-stakes healthcare settings, according to an Ohio State study.
•EurekAlert
AI Dramatically Improves Prediction of Delivery Timing from Ultrasound Images
Ultrasound AI's study validates advanced AI for predicting delivery timing using standard ultrasound images.
•EurekAlert
AI Voice Analysis Shows Promise for Early Laryngeal Cancer Detection
Researchers demonstrated AI could detect early laryngeal cancer from voice recordings, distinguishing it from benign conditions.